Gray Matter Solutions is a MedTech spin-off from NTU Singapore building the infrastructure for early brain health — where screening, subtyping, and intervention converge into a single AI-powered platform. Its flagship product, ReCOGnAIze, is the first digital test globally to differentiate Vascular MCI other forms cognitive impairment, validated against brain scans and blood biomarkers with published clinical evidence. A second product, RevitalAIze, closes the loop with personalised cognitive training. The company is regulatory-listed in Singapore and Malaysia, ISO 13485 certified, and already deployed commercially across clinic networks in Southeast Asia with pharma partnership revenue in motion. GMS sits at the intersection of three massive tailwinds: ageing populations, Alzheimer's drug approvals, and the shift toward preventative, data-driven care.